|
advertisement
|
Company Overview: |
Antigenics is a biotechnology company that is involved in the development of therapeutic drugs for treating many serious diseases. The company’s central technology platform used for development of drug treatment is based on HSP-peptides, which are biological structures associated with the immune system’s reaction to disease. Antigenics' technology and products are developed through the manipulation of these peptides. HSP-peptide complexes created from tumor cells or other pathogen-infected cells are able to promote immunity at the cellular level and help them to destroy disease. Antigenics understands the widespread potential applications of this technology as treatments for multiple diseases while emphasizing the impact on the field of oncology.
Antigenics scientists have commenced on various tracks of research formats that concentrate on finding viable therapeutics that can be used for the treatment of cancer, infections such as like herpes, malaria and AIDS as well as immune disorders like diabetes or multiple sclerosis. The company is also hard at work researching Alzheimer’s disease as well as other degenerative neurological diseases.
|
Products and Services: |
| Antigenics’ primary technology platform has been in the field of Immunology and includes those types of products which activate both the cellular and antibody portions of the body’s immune system. The company is developing drug treatment therapies that will have medical applications as potential treatments for conditions like cancer, infections, autoimmune and degenerative diseases. In fact, cancer drug treatment represents Antigenics' most advanced therapeutic area to date and includes a short list of internally developed and externally acquired drugs. It is this singular success with cancer drug development which molds and shapes, the biotechnology company’s business strategies because it is focused upon the full-scale development as well as commercial distribution of its cancer programs to multiple markets in the United States and beyond. |
Key Personnel Facts: |
Garo H. Armen: CEO and Chairman
Shalini Sharp: Vice President and Chief Financial Officer
Deanna M. Petersen: Vice President, Business Development
Margaret Eisen: Director
Elma S Hawkins: Vice Chairman
Gamil G. de Chadarevian: Vice Chairman
Employees (2006): 273
1-Year Employee Growth: 37.4%
|
Key Financial Facts: |
Fiscal Year-End: December
Sales (2005): $0.6M
1-Year Sales Growth: 11.3%
Net Income (2005): $74.1M
|
Back to Top
|
|
Working @ Antigenics
Have your shout about working or interveiwing at Antigenics
1 message posted
Message Posted:
Working @ Antigenics
Share your experiences about working, interviewing or applying for a job at ...
Author: Obi Posted: 3/3/2007 6:54:07 AM |
View or add comments about Antigenics
Back to Top
|
Antigenics in the News
- Antigenics to Report Second Quarter 2007 Financial Results on August 2, 2007; Conference Call to Follow (Business Wire)
Published: Thursday, July 26, 2007
- John Hatsopoulos Joins Antigenics' Board of Directors (Business Wire)
Published: Monday, June 11, 2007
- Antigenics Product Part of Glaxo Study (AP)
Published: Tuesday, June 05, 2007
- Antigenics' QS-21 Stimulon(R) Adjuvant Enters Phase 3 Clinical Trial of GlaxoSmithKline's Novel Cancer Immunotherapeutic in Non-Small Cell Lung Cancer (Business Wire)
Published: Tuesday, June 05, 2007
- Antigenics, Cephalon shares drop
Published: Friday, March 24, 2006
View more news about Antigenics
Back To Top |
|
|
|
|
Categories:
|
Biotechnology
|
|
Back to Top
|
|
|
|